Ponatinib is a first generation tyrosine kinase inhibitor with activity against a broad range of receptor tyrosine kinases, including FLT3 (reviewed Pemmeraju et al, 2014; Kazi and Roonstrand, 2019). This pathway describes FLT3 mutants that are resistant to inhibition by ponatinib.
Kazi, JU, Rönnstrand, L
Cortes, J, Kantarjian, H, Pemmaraju, N, Ravandi, F, Andreeff, M
© 2023 Reactome